Immunome, Inc.
IMNMImmunome, Inc. (IMNM) is a biotechnology company focused on discovering and developing immune-based therapies for infectious diseases, cancers, and other conditions. The company utilizes its proprietary platform to identify novel targets and develop therapeutics that modulate the immune system. Immunome aims to address unmet medical needs through innovative antibody and vaccine development.
Company News
Jack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares (30% of his direct holdings) for approximately $204,000 on April 2, 2026, through a pre-arranged Rule 10b5-1 trading plan established in December 2025. The sale represents routine financial diversification rather than a bearish signal, as Higgins maintains a substantial $480,00...
In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somew...
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
